Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

ermune.com">www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ... financial results for the second fiscal quarter ended September 30, 2011 ("2Q ... 1and Six M onths Ended ... Three   Months   EndedSeptember   ...
... LOUIS, Nov. 17, 2011 United Seating & Mobility (USM) ... transaction with The Rehab Specialist (TRS) to acquire and merge ... the Raleigh/Durham area. "The addition of Dana Mazer, ... growth market for USM and supports our regional initiative in ...
Cached Medicine Technology:China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14China Medical Technologies Reports Second Fiscal Quarter Financial Results 15China Medical Technologies Reports Second Fiscal Quarter Financial Results 16China Medical Technologies Reports Second Fiscal Quarter Financial Results 17China Medical Technologies Reports Second Fiscal Quarter Financial Results 18China Medical Technologies Reports Second Fiscal Quarter Financial Results 19China Medical Technologies Reports Second Fiscal Quarter Financial Results 20China Medical Technologies Reports Second Fiscal Quarter Financial Results 21China Medical Technologies Reports Second Fiscal Quarter Financial Results 22China Medical Technologies Reports Second Fiscal Quarter Financial Results 23China Medical Technologies Reports Second Fiscal Quarter Financial Results 24
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... more likely to become addicted to cigarettes if they carry a ... of the liver. ,Those with the inactive form of the ... the habit than those with the normal form. The study authors ... smoke as many cigarettes. In a study, carried out among seventh ...
... for long hours does not only cause fatigue but ... that flying on an airplane for several// hours can ... blood clots form in the leg or pelvic veins. ... health conditions that promote clotting, such as cardiovascular disease, ...
... cancer risk in men, but not in women, say ... conducted a study on 13,017 French adults. The participants ... containing 120 milligrams of ascorbic acid (vitamin C), 30 ... 100 micrograms of selenium, and 20 milligrams of zinc.,Results ...
... children with depression may have an adverse effect on ... say they found a reduction in bone mass and ... Prozac. Fluoxetine is the only prescription antidepressant currently approved ... preliminary studies show the use of selective serotonin-reuptake inhibitors, ...
... drugs may slow mental decline and improve symptoms of ... pilot study was conducted to test the drug on ... patients were followed for one year, twenty-five of the ... patients received a placebo. All of the patients in ...
... diabetes have a risk of developing high blood pressure. ... // in the eye, which are characteristic of eye ... shows good blood pressure control significantly lowered the risk ... ultimately lead to blindness. ,For the study researchers ...
Cached Medicine News:
... only control for monitoring total ... fluid samples performed manually using ... an aid for identifying the ... pathological condition present in the ...
... use with Leica Unistat and ... and all automated bilirubin methods ... AU Series, Cobas, Dimension, Hitachi, ... contain purified bilirubin in a ...
... The Dropper Plus is specifically designed for ... room temperature stability eliminates storage problems and ... without refrigeration. A new feature is the ... provided for all analytes; qualitative results for ...
... the ultimate in convenience for urinalysis quality ... DipandSpin is a combination product for dipstick, ... feature is the addition of creatinine and ... as well as for all analytes; qualitative ...
Medicine Products: